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Abstract
Lecithin:cholesterol acyltransferase protein (LCAT) promotes the esterification reaction
between cholesterol and phospholipid-derived acyl chains. Positive allosteric modulators
have been developed to treat LCAT deficiencies and, plausibly, also cardiovascular dis-
eases in the future. The mechanism of action of these compounds is poorly understood.
Here computational docking and atomistic molecular dynamics simulations were utilized to
study the interactions between LCAT and the activating compounds. Results indicate that
all drugs bind to the allosteric binding pocket in the membrane-binding domain in a similar
fashion. The presence of the compounds in the allosteric site results in a distinct spatial ori-
entation and sampling of the membrane-binding domain (MBD). The MBD’s different spatial
arrangement plausibly affects the lid’s movement from closed to open state and vice versa,
as suggested by steered molecular dynamics simulations.
Author summary
High-density lipoprotein (HDL) particles play a crucial role in reverse cholesterol trans-
port, whose efficiency is linked to the development of coronary heart disease (CHD), a
global health threat showing an increased prevalence in industrial as well as in developing
countries. While many drugs for treating CHD exist, e.g., the cholesterol-lowering statins,
a substantial residual vascular risk remains, thus calling for novel therapeutic interven-
tions. One of these approaches is to elevate the activity of lecithin:cholesterol acyltransfer-
ase (LCAT) enzyme by, e.g., positive allosteric modulators. However, although
modulators’ allosteric binding site is known, it is not understood how these compounds
can promote the activity LCAT. Therefore, in this article, we aimed to clarify how a set of
positive allosteric modulators affect the structural and dynamical properties of LCAT uti-
lizing atomistic molecular dynamics simulations and free energy calculations. Shortly, our
findings suggest that the reorientation and the different energetic landscape of the MBD
induced by the allosteric compounds may facilitate the lid’s opening, therefore providing
a plausible explanation of why the set of positive allosteric modulators promote the
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activity of LCAT. Besides, this finding is also insightful when deciphering how apoA-I, the
principal LCAT activating apolipoprotein in HDL particles, facilitates the activation of
LCAT.
Introduction
Lecithin:cholesterol acyltransferase (LCAT) is an enzyme that is responsible for producing
cholesterol esters (CEs) in circulation by linking the acyl chains of phospholipids to cholesterol
(CHOL) molecules. LCAT mediated CE formation predominantly occurs in high-density lipo-
protein (HDL) particles in which apolipoprotein A-I (apoA-I) serves as a cofactor for the reac-
tion. After the formation of CEs, the morphology of HDL particles transforms from discoidal
to spherical by the creation of a non-polar CE phase, which is shielded from aqueous sur-
roundings by an amphiphilic monolayer comprised of phospholipids, CHOL, and apolipopro-
teins. Owing to this, the action of LCAT is an essential step in HDL-mediated reverse
cholesterol transport (RCT), in which intracellular CHOL and phospholipids are transported
from extrahepatic tissues to the liver. Importantly, HDL particles also remove CHOL from
lipid droplet-laden macrophages that are the hallmark of early atherosclerotic lesions in the
arterial intima [1]. For this reason, chiefly, RCT’s efficiency is hypothesized to be associated
with the progression of coronary heart disease (CHD) [2–4].
The normal functioning of LCAT is reduced or completely lacking in individuals suffering
from the autosomal recessive disorders familial LCAT deficiency (FLD) and fish-eye disease
(FED) [5–7]. The clinical manifestations of LCAT deficiency include diffuse corneal opacities,
target cell hemolytic anemia, and kidney failure. While the role of LCAT deficiencies and
activity in CHD progression is currently far from understood, multiple ongoing research pro-
grams are attempting to shed light on LCAT activity’s boosting therapies in this context. These
therapeutic approaches include recombinant human LCAT (rhLCAT) injections, biologics
such as peptides and antibodies, and small molecular activators [8–11]. The rhLCAT
(MEDI6012, formerly ACP-501) is particularly of note as during recent phase II trials, it was
shown not to cause any serious adverse events in the 48 participants, and its administration led
to a dose-dependent increase in HDL-cholesterol (HDL-C) concentration [12]. Intriguingly, a
recent HDL particle lipidomics study in which a subsequently defined non-equilibrium reac-
tion quotient describing global CHOL homeostasis in circulation was established suggests a
deficient conversion of CHOL to CE in CHD patients when compared to controls [13]. Nota-
bly, the deficient CHOL to CE conversion was determined without utilizing LCAT activity
assays or plasma concentration measurements. Hence, this approach might provide a more
reliable means to assess LCAT mediated CHOL to CE conversion that considers the effect of
native lipid compositions better than exogenous plasma assays that are based on, e.g., the addi-
tion of labeled CHOL molecules into the plasma of individuals with differing amount of
CHOL in different lipoprotein pools.
Because of the reasons above, it would be valuable to develop LCAT activity promoting
therapeutics, firstly, for the treatment of different LCAT deficiencies and, secondly, for provid-
ing additional ways to elucidate the impact of LCAT based therapeutics on the functional qual-
ity of HDL particles in the context of RCT and CHD. In this respect, a set of promising LCAT
activity-promoting compounds was developed by Daiichi Sankyo [14–17]. Recently, out of
this set of compounds, the piperidinyl-pyrazolopyridine derivatives (compounds 1, 2, 3, 6, 8,
and 9) were further investigated by Manthei et al., showing that the compounds increase the
activity of LCAT up to 3.7-fold [18]. In the same study, an X-ray structure for LCAT was
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solved, with both bound activator compound 1b and inhibitor isopropyl dodecyl fluoropho-
sphonate (IDFP), revealing that compound 1b resides in the cleft of the membrane-binding
domain (MBD, see Fig 1). Although the MBD has been shown to interact with lipids when
LCAT is bound to lipid bilayers or HDL particles [19–22], it became evident based on binding
studies that the activators do not alter the association of LCAT with discoidal HDL particles
[18]. In addition, the X-ray structure revealed that compound 1b forms hydrogen bonds with
MET49, TYR51, ASP63, and ASN78 residues (Fig 1) and possesses the enantiomeric R state
(compound 1b in Fig 2).
Interestingly, previous hydrogen-deuterium exchange (HDX) studies indicated that the α-
helical folds a1 and a2 (comprised of amino acids 63–75) in the MBD and the lid loop region
are more dynamic when compared to the rest of the LCAT structure (Fig 1). It was further
demonstrated that the binding of IDFP decreased HDX in the a1-a2 region. While the X-ray
Fig 1. The structure of LCAT with compound 1b bound to the allosteric site. The α/β hydrolase domain is colored as purple, the cap
domain as gray, and the membrane-binding domain as green. The a1-a2 region of the MBD (amino acids 63–75) is marked with
orange. The protein is rendered as a cartoon secondary structure representation and the compound as blue sticks. The compound
(hued blue) and the amino acids ASN78, ASP63, TYR51, and MET49 are rendered with sticks and colored according to the element
types. Carbon atoms are cyan, oxygen red, nitrogen blue, fluorine pink, and sulfur yellow.
https://doi.org/10.1371/journal.pcbi.1008426.g001
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structure of LCAT with bound compound 1b and IDFP also indicated that the temperature
factors are slightly decreased in the a1-a2 site when compared with LCAT structures without
drugs, it is impossible to determine what is the impact of compound 1b alone on the dynamics
of the a1-a2 region and the whole MBD in general. Besides, the constraints imposed by differ-
ent crystal lattices might not reveal real conformational preferences for the local structural
domains of enzymes compared to conditions in which the enzymes are in fully aqueous sur-
roundings and under the influence of the Brownian motion. Significantly, this might be the
case when highly mobile regions of proteins are considered. Nevertheless, the binding of IDFP
alone might induce the opening of the lid as was suggested by the HDX data [23] and, there-
fore, the conformation of the lid loop in the X-ray structure of LCAT with bound compound
1b might not resemble the case when compound 1b is solely present. However, as compound
1b forms hydrogen bonds with the two amino acids located in the a1-a2 region, namely with
ASP63 and ASN78, it might have an additional effect on, e.g., the rigidity of the region that
may play an essential role in the activation of LCAT.
Consequently, our aim in this study was to computationally characterize how the set of pos-
itive allosteric modulators previously investigated by Manthei et al. [18] interact with the MBD
and if they alter its conformation and dynamics. This, particularly, without the presence of the
inhibitor IDFP. Firstly, we utilized molecular docking calculations and atomistic molecular
dynamics simulations to show that the compounds interact with LCAT through a varying
number and network of hydrogen bonds, which presumably stabilizes the MBD. Secondly,
Fig 2. (A) The chemical structures of the compounds studied. (B) The docking poses of the compounds bound (hued purple) in the MBD cleft of LCAT and the co-
crystallized compound 1b (PDB accession code 6MVD; hued blue) compared to its position docked back the structure (hued red). The allosteric site of LCAT is
rendered as a cartoon secondary structure representation and shown as green. The compounds and the significant amino acids are rendered as sticks and are colored
according to different elements. Carbon atoms are cyan, oxygen red, nitrogen blue, fluorine pink, and sulfur yellow.
https://doi.org/10.1371/journal.pcbi.1008426.g002
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simulations highlight that the drugs adjust the MBD’s spatial orientation with respect to the lid
in its open state. Meanwhile, accelerated weight histogram-based free energy simulations dem-
onstrate that the compounds modify the MBD’s energetic landscape.
Further, steered molecular dynamics simulations reveal that enforcing the lid loop to a
close state is accompanied by a retraction of the MBD away from the lid binding cavity. To
conclude, our findings suggest that the reorientation and the different energetic landscape of
the MBD induced by the allosteric compounds may facilitate the lid’s opening, therefore pro-
viding a plausible explanation of why the set of positive allosteric modulators studied here pro-
mote the activity of LCAT. Besides, this finding may be insightful when deciphering how
apoA-I facilitates the activation of LCAT. In general, the results provided here pave the way
for the design of new therapeutic approaches against LCAT deficiencies and for scrutinizing
the HDL quality hypothesis in the context of RCT and CHD.
Materials and methods
Construction of the LCAT structure
The X-ray structure of LCAT with bound molecular activator compound 1b [18] was acquired
from the Brookhaven databank (PDB ID code:6MVD). The missing two amino acid residues
located at the lid region of LCAT were incorporated into the structure with the Modeller
homology modeling package, as described earlier [19,24]. The standard parameters were used
in the incorporation, and the structure with the lowest DOPE score was selected for the further
modeling stages.
Docking calculations
The molecular structures and initial coordinate files for all compounds were built with the
Avogadro molecular editor and visualizer software [25], after which the compounds were
docked to the membrane-binding domain of LCAT utilizing the Autodock Vina version 1.1.2
[26]. The size of the docking grid was set big enough to cover the membrane-binding domain
of LCAT. The number of grid points was set to 80 in the X, Y, and Z dimensions when the grid
points’ distance was 0.375 Å. The exhaustiveness was set to 100. Nine docking configurations
with the lowest binding free energies were produced, and the lowest one was selected as a start-
ing point for molecular dynamics simulations.
Force fields and parametrization of drug compounds for molecular
dynamics simulation purposes
The AMBER99SB-ILDNS force field parameter set was used to describe the LCAT protein
[27]. Water was described by the TIP3P parameters [28]. The initial structures for the drug
compounds were built with the Avogadro program, after which the geometries of the com-
pounds were optimized with the Gaussian software version 16 revision A.03 [29]. Hartree-
Fock method and 6-31G� basis set were used in the optimization procedure. The partial char-
ges were derived by first determining the electrostatic potential around each molecule with the
Gaussian program utilizing the Merz-Kollman scheme [30]. The same method and basis set
was employed in this stage as in the geometry optimization step. This was followed by the deri-
vation of partial charges utilizing the restrained electrostatic potential (RESP) method to pro-
duce the QM-derived electrostatic potentials around the molecules. The antechamber
program included in the Amber18 modeling package was used for this purpose [31]. The Len-
nard-Jones and bonded parameters for the compounds were taken from the GAFF force field
[32].
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Simulated systems and simulation parameters
The structure of LCAT with and without drugs was placed into the center of a box with dimen-
sions of 10 x 10 x 10 nm. Two replicates were run for the LCAT system without drugs. The
compounds were incorporated into the allosteric binding site of the MBD domain based on
the docking results. Each system was solvated, resulting in 14597 water molecules per system.
Ions were added to neutralize the total charges of the systems. All simulations were coupled to
a temperature bath of 310 K utilizing the v-rescale thermostat with a coupling constant of 0.5
ps [33]. The 1.013 bar pressure was described as isotropically using the Parrinello-Rahman
barostat with a coupling constant of 10 ps [34]. To handle electrostatics, the Particle-Mesh
Ewald (PME) summation scheme was employed with a real-space cut-off of 1.0 nm [35]. The
Lennard-Jones interaction cut-off was set to 1.0 nm. All systems were first energy minimized
utilizing the steepest descent method followed by molecular dynamics simulations up to 1 μs
with the GROMACS simulation package [36,37].
Accelerated weight histogram simulations
The accelerated weight histogram method is an adaptive biasing method implemented in the
GROMACS package that can be employed to calculate the potential mean force profiles as a
function of reaction coordinates [36,37]. The approach flattens the free energy barriers along a
reaction path by introducing potentials that elevate free energy minima resulting in unre-
stricted diffusion of the selected atoms or molecules along the reaction coordinate. Therefore,
the system’s sampling is artificially enhanced, and the spatial free energy can be explored,
unlike in non-adaptive biasing simulations [38]. In this study, the AWH method [38,39] was
employed to probe the free energy profile when the MBD domain of LCAT changes its orien-
tation with respect to the lid. The α-carbon atoms of amino acids I231 and M66 were chosen
as the reference and pull groups, respectively. The reaction coordinate was defined as the dis-
tance between these two atoms, with the largest distance being 1.1 nm and the smallest 0.5 nm.
The AWH potential was set to the umbrella, and the force constant and initial error for AWH
calculations were set to 128000 kJ/mol/nm2 and 5 kJ/mol, respectively. The estimated diffusion
parameter of 0.0001 nm2/ps was used for the coordinate dimension. The AWH systems were
simulated up to 500 ns. The convergence of free energy profiles and distribution profiles were
registered to take place after 300 ns (Fig D in S1 Text). The free energy profiles after 500 ns
simulations were constructed utilizing the gmx awh program included in the GROMACS sim-
ulation package.
Steered molecular dynamics simulations
To monitor the movement of the MBD domain of LCAT during the conformational change of
the lid from the open to a closed state, we carried out steered molecular dynamics simulations
during which the lid was pulled to a closed state. The center of mass α-carbon atoms of amino
acids 110–130 was used as a reference group during the pulling simulation, whereas the α-car-
bon atom of amino acid 219 was pulled towards the center of mass of the reference group. The
pulling force constant and the rate was set to 5000 kJ/mol�nm2 and 0.0001 nm/ps, respectively.
The steered MD simulations were run up to 25 ns, after which the distance between the α-car-
bon of LEU239 and the reference group was approximately 1 nm. The distance of MET66 Cα
atom from its initial position was monitored as a function of simulation time to reveal the
retraction distance of MBD when the lid is pulled to a closed state. During the pulling, the pro-
tein’s rotational and translational movement was kept fixed by spatially restraining the refer-
ence group’s backbone atoms.
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Analysis
Hydrogen bonds and distances were calculated using the gmx hbond and gmx mindist tools,
respectively, that are included in the GROMACS package. The default hydrogen bond parame-
ters were used in determining the number of hydrogen bonds formed between the drugs and
LCAT. The number of hydrophobic interactions between the drugs and relevant amino acids
was measured with gmx mindist using carbon-carbon or carbon-fluorine pairs and a cut-off of
0.4 nm. The accessible surface areas (ASA) of drugs were calculated with gmx sasa using the
standard van der Waals volumes and radii [40]. The surface areas between the drugs and the
binding cleft were further determined by subtracting the solvent ASAs from the drugs’ total
ASAs. The Visual Molecular Dynamics (VMD) program was used to visualize and render the
figures [41].
Results and discussion
All compounds bind similarly into the allosteric cleft located in the MBD of
LCAT
In order to investigate the differences between the binding poses of different compounds and to
produce starting configurations for atomistic molecular dynamics simulations, all compounds
were docked to the MBD of LCAT (PDB accession code: 6MVD, co-crystallized with com-
pound 1b) utilizing the AutoDock Vina docking software [26]. The chemical structures for all
drug compounds are shown in Fig 2A. Firstly, compound 1b was docked back into the MBD to
validate the parameters and the scoring function used in the docking. As seen in Fig 2B, the
Autodock program was able to find the correct pose for compound 1b, with only small differ-
ences seen mainly in the water-exposed part of the drug. It is also good to note that in the X-ray
structure of LCAT bound to compound 1b (6MVD), compound 1b interacts with the neighbor-
ing LCAT enzyme in the crystal lattice. This likely also affects the orientation of the water
exposed part of the compound in the allosteric site. After this, the rest of the compounds (2a,
2b, 3, 6, 8, and 9) were docked similarly to the MBD. In the case of compound 6 both the neutral
and charged form were investigated (Fig 2A). Afterward, we docked the compounds again into
the allosteric site after 1 μs of atomistic simulations to see if carrying out the simulations would
improve binding as far as the Autodock derived binding free energies are concerned.
As expected, the results in Fig 2B point out that the preferred orientation of molecules in
the allosteric site is similar in each case. While tiny differences in the spatial arrangement are
seen, this is expected since the chemical groups, and their spatial regions are also different
between the molecules. We found out that 1 μs simulations increased the negative binding free
energies in all cases except in the case of compound 6 (Table 1). Namely, the negative binding
free energy change of compound 6 decreased (neutral form) or stayed the same (charged
Table 1. The calculated binding free energies for the compounds docked either to the X-ray structure or the simu-
lated structure of LCAT (after 1 us).
Molecule DGbind(X-ray) [kJ/mol] DGbind (Sim.) [kJ/mol]
Compound 1b -37 -41
Compound 2a -34 -42
Compound 2b -39 -40
Compound 3 -35 -38
Compound 6 -34 -32
Compound 6 (charged) -33 -33
Compound 8 -34 -39
Compound 9 -36 -41
https://doi.org/10.1371/journal.pcbi.1008426.t001
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form) after the simulation and is lower than those of the rest of the compounds (-32 kJ/mol vs.
-38 to -42 kJ/mol, respectively). This finding follows the previous experimental findings show-
ing that compound 6 does not activate LCAT since its binding, for some reason, is abolished
[18]. However, our docking calculations and simulations (in the later chapter) imply that com-
pound 6 can favorably interact with the allosteric site if it can access it. As the binding free
energies change somewhat after the 1 μs simulations (except for compound 6), it also suggests
that the compounds and the allosteric site become better adapted to each other during the sim-
ulations. The binding free energies of the compounds do not correlate with the experimental
fold activities produced with MUP esterase assays, implying that the strength of binding does
not explain the different fold activities [18].
All drug compounds form a stable hydrogen bonding network in the
allosteric site
The binding free energies derived from the docking calculations do not reveal if there are free
energy barriers along the pathway which the drugs take when entering the allosteric site. Yet,
the free energy barrier along the entry pathway could explain the abolished binding of com-
pound 6 registered in experiments. To investigate this, we carried out umbrella sampling simu-
lations to reveal possible barriers for compounds 6 (abolished binding) and 8 (the highest fold
activity). We calculated PMF profiles for both the neutral and charged forms of compound 6.
Indeed, the results indicated that there exist free energy barriers with heights of 10 ± 4 kJ/mol,
20 ± 5 kJ/mol, and 6 ± 3 kJ/mol at the allosteric site opening for neutral compound 6, charged
compound 6, and compound 8, respectively (Fig A in S1 Text).
However, we are not certain if the free energy barrier of 20 kJ/mol is sufficient to kinetically
prevent the charged form of compound 6 from binding to the allosteric site at the physiological
pH of 7.4, since e.g. the dissociation constants and corresponding binding free energies of -20
kJ/mol for compounds can be determined by experimental methods (such as surface plasmon
resonance technique) in which association and dissociation rates are utilized to derive the dis-
sociation constants for biomolecular complexes. That is, in certain experimental settings the
free energy barrier of 20 kJ/mol does not kinetically prevent the dissociation of molecular com-
plexes when the strength of binding is determined. To verify the existence of such a high free
energy barrier in the case of compound 6 association rate constants could be determined as a
function of temperature after which the Arrhenius law could be employed to estimate the acti-
vation energy which should be comparable to the free energy barrier. Nonetheless, the
umbrella sampling derived binding free energies were similar, and the difference was not sig-
nificant between compounds 6 and 8: -43 ± 3 kJ/mol (neutral compound 6) and -38 ± 3 kJ/
mol (charged) compound 6 vs. -40 ± 3 kJ/mol (compound 8). Thus, the binding of both com-
pounds is thermodynamically favored but could be kinetically too slow to occur and to be reg-
istered in experiments. In addition, it should be mentioned here that the basic functional
amine group of piperidine is exposed to the water phase when both forms (neutral and
charged) of compound 6 are bound to the allosteric site. Namely, the charged group will not
become buried during the binding and, thus, should not considerably affect the binding free
energy of compound 6 as can be seen from the binding free energies derived by docking calcu-
lations and free energy simulations. Thus, the notably larger free energy barrier for the charged
form of compound 6 was not expected.
To gain more insight into how the LCAT activators interact with the MBD domain of
LCAT, we analyzed the average number of hydrogen bonds formed between the compounds
and LCAT. Besides, we identified the critical amino acid residues taking part in the formation
of the hydrogen bonds with the different functional groups of the drug compounds.
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Fig 3A shows the average number of hydrogen bonds between the compounds and the dif-
ferent residues in the MBD domain. Based on the data, it is evident that mainly ASP63,
TYR51, and ASN78 form hydrogen bonds with the compounds. However, the backbone
amine of MET49 showed a stable hydrogen bond with compounds 1b and 2b throughout the
simulations. In the case of ASP63 and ASN78, the side chain amine and carboxyl groups were
involved in forming hydrogen bonds with the hydroxyl and carbonyl groups of the com-
pounds, respectively (Fig 3C). TYR51 formed hydrogen bonds through the backbone amine
and carboxyl groups. MET49 utilized the backbone carboxyl oxygen to bond with the amine
groups of compounds 1b and 2b. Compound 2a did not form a hydrogen bond with MET49,
which can be traced to the changed amine hydrogen position, which abolishes the hydrogen
bond interaction with MET49. Instead, compound 2a forms a hydrogen bond with TYR51. In
addition, the amine hydrogen hopping increases the average number of hydrogen bonds
formed with TYR51 above all other compounds, as seen in Fig 2A. Compound 9 also forms a
more significant number of hydrogen bonds with TYR51 and this, in turn, arose from the
close location of two hydrogen acceptors, ring oxygen and nitrogen of compound 9, which
enabled them to bond with the backbone amine of TYR51 at the same time.
Our simulations show that all drug compounds form hydrogen bonds similarly with
ASP63, ASN78, and TYR51, consistent with the X-ray structure of LCAT co-crystallized with
compound 1b. However, in addition to compound 1b, only compound 2b formed a hydrogen
Fig 3. (A) The average number of hydrogen bonds formed between the MBD amino acids and drug compounds during the whole simulation trajectory. (B) The
average number of hydrophobic interactions between drugs and amino acids showing the most variation for compound 8 relative to other compounds. (C) Visualization
of the primary hydrogen bonding pairs between compounds and LCAT. Snapshots from Drug-1B (Top) and Drug-2A (Bottom) simulations showing the conformations
of compounds 1b and 2a in the cleft of MBD. The hydrogen bonds between drugs and amino acids are marked with black dashed lines. Compounds 1b and 2a are
rendered as sticks and are colored according to the element types. Compound 1b is hued purple and 2a orange. The MBD cleft is rendered as a cartoon representation
and colored green. Amino acids forming hydrogen bonds with compounds are rendered as sticks and colored according to the element types. Carbon atoms are cyan,
oxygen red, nitrogen blue, fluorine pink, and sulfur yellow.
https://doi.org/10.1371/journal.pcbi.1008426.g003
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bond with MET49. Therefore, it seems that the amine group with a hydrogen donor at site 1
(Fig 3A) is required for the formation of an efficient hydrogen bond with the backbone carbonyl
group of MET49. Without hydrogen at site 1, the amine group forms a hydrogen bond with the
backbone amine of TYR51. The compounds studied here were partly chosen to explain the
MUP esterase assay’s differences conducted by Manthei et al. 2018 [18]. Out of these, the lack of
activity of compound 6 was of particular interest. As seen in our simulation analysis, compound
6 formed hydrogen bonds with the same amino acids (ASP63, TYR51, and ASN78) as the other
compounds. Besides, no significant differences were detected in the average hydrogen bond
numbers between compound 6 and the rest of the compounds, indicating that the hydrogen
bonds are equally stable. Furthermore, according to the MUP esterase activity assays, com-
pounds 1b, 2b, 3 had the same fold activities (2.3–2.4), whereas compounds 8 and 9 possessed
the highest and lowest activation potencies (3.7 vs. 1.6), respectively. Based on our hydrogen
bonding results here, we cannot argue the reason behind the different potencies.
In addition to the hydrogen bonds, the average number of hydrophobic interactions was
also determined between the drugs and all relevant nearby amino acid residues. Once more a
direct connection to the fold activities was not discovered, but compound 8 (highest fold activ-
ity) separated significantly from the rest. The differences were most visible in contacts to
ASP63, MET66, GLY71, and TRP75, measured for all drugs at Fig 3B. This is naturally due to
the lack of a hydroxyl-group and the presence of a double bond in compound 8, which forces
the trifluoromethyl-group towards different residues. Whether this phenomenon is the cause
of a higher fold activity, or merely benefits drug entry into LCAT is impossible to say, as com-
pound 8 doesn’t induce a different conformational change compared to the other compounds
as discussed later. The full data is available in Table A in S1 Text. Hydrophobic interactions
were further analyzed with accessible surface areas, but nothing relevant was discovered
(Table B in S1 Text).
Positive allosteric modulator binding induces a conformational change
which distances the MBD from the lid residing cavity
Next, we aimed to investigate if the compounds change the spatial arrangement of the MBD of
LCAT. We calculated distances between the backbone α-carbon atoms of the MBD and the lid
loop to determine if the compounds rearrange the MBD with respect to the rest of the enzyme.
Upon examining the distance matrix, a conformational change was discovered where systems
with drugs had the MBD pushed further from the lid loop and cavity (Fig 4A). Since the dis-
tance matrix analysis showed the average distances over the whole simulation trajectories, we
examined how consistent the conformational shift was by monitoring the distance between
the backbone α-atoms of M66 and I231 as a function of time (Fig 4B). It was found that the
distance between the backbone α-atoms was persistently more considerable in the simulations
with drug compounds bound, except in the case of charged compound 6, to the allosteric site
than in simulations without allosteric modulators. This conformational shift is illustrated in
Fig 4C with two snapshots with and without drug molecules. To ensure that our shift is genu-
inely dependent on whether a compound is bound to the allosteric site or not, we removed
compound 2a from the LCAT structure after an 800 ns simulation. As seen in Fig 4D, the dis-
tance between the α-atoms decreased from 0.9 to 0.7 nm in 50 ns, indicating that the MBD
shifts its orientation closer to the lid cavity in the absence of the drug.
We also determined the energetics of the MBD movement by utilizing the accelerated
weight histogram method to calculate the free energy profiles as a function of the distance
between the α-carbon atoms of M66 and I231. Free energy simulations were carried out with
and without compound 2a. Fig 5 shows that the free energy minima at the distances of 0.7 and
PLOS COMPUTATIONAL BIOLOGY Effect of positive allosteric modulators on lecithin: Cholesterol acyltransferase
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1008426 March 15, 2021 10 / 16
Fig 4. (A) The average distances between the relevant residues mapped as a distance matrix plot. Drug 2a is used as an example as the rest of the compounds induced
a similar change. (B) The distance between the α-carbon atoms of M66 and I231 as a function of time in Drug-2a and Nodrug-2 simulations (Left). The average
distances between the α-carbon atoms of M66 and I231 for all simulated systems (Right). (C) Snapshots from Drug-2a and Nodrug-2 simulation showing the maxima
and minima of the detected conformational change. The proteins are rendered as cartoons and the marker residues’ α-carbons as red spheres. (D) The distance plot
derived from the simulation where compound 2a was removed from the allosteric site after 800 ns (Left). Two simulation snapshots superimposed showing the
orientation of the MBD domain before (0 ns; green) and after the removal of compound 2a (120 ns; blue) (Right).
https://doi.org/10.1371/journal.pcbi.1008426.g004
Fig 5. (Left) Spatial energetics of the MBD. The free energy profiles as a function of the distance between M66 and
I231 α-carbon atoms with and without compound 2a. (Right) A blue cartoon presentation of LCAT showing the
ILE231 and MET66 Cα atoms (red spheres) that were used to determine the conformational free energy as a function
of distance.
https://doi.org/10.1371/journal.pcbi.1008426.g005
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0.9 nm agree with the distance analysis. Interestingly, the profiles show that when compound
2a is bound to the allosteric site, ~10 kJ/mol of energy is needed to move the MBD domain
closer to the lid residing cavity. However, the energy required to move the MBD away from
the lid cavity is smaller (~6 kJ/mol). This finding indicates that the drugs are hindering the
MBD movement closer to the lid-residing cavity, which results in the broader cavity. Centered
on this finding, we hypothesize that the wider cavity promotes the lid movement from a closed
state to an open one and vice versa due to lessened steric hindrance. To shed more light on
this, we transformed the lid loop from the open state to a closed state by slowly pulling the lid
loop towards the active site tunnel opening. At the same time, we monitored the distance of
the α-carbon atom of M66 from the initial position as a function of pulling time. As seen in
Fig 6, the MBD domain moves away from the initial position (~0.3–0.5 nm) when the lid
changes its conformation from an open to a closed state. The use of a lower force constant dur-
ing pulling did not affect the results (Fig C in S1 Text). However, we must remark that our
pulling experiments do not necessarily resemble the correct conformational change pathway
for the lid as the lid’s exact folding pathway during the transition is not known. Nevertheless,
our pulling results further support the hypothesis that the MBD needs to shift its orientation to
render the lid’s conformational shift possible.
In the light of these findings, it is tempting to hypothesize that the MBD’s reangling is
responsible for the increased activity of LCAT bound with different drugs in the MUP esterase
assays reported by Manthei et al. [18]. Intriguingly, while the neutral form of compound 6
induced the same orientational change of the MBD when compared to the other drug com-
pounds, the charged form did not. While it was shown in experiments that compound 6
(charged at the physiological pH of 7.4) did not bind to LCAT in experiments, our results sug-
gest that even if the charged form of compound 6 could bind to the allosteric site it cannot pro-
mote the activity of LCAT. Regarding this, our docking calculations showed highly favorable
binding energies for compound 6 in both forms and were comparable to the binding free ener-
gies of other compounds. However, as docking calculations do not consider the drug’s intro-
duction into the allosteric site, we conducted free energy simulations with results indicating
that compound 6’s entry is accompanied by a relatively high free energy barrier when com-
pared to compound 8, which showed the highest fold activity in LCAT assays in previous
experiments. Therefore, plausibly, the relatively high free energy barrier can kinetically prevent
Fig 6. (Left) Steered molecular dynamics analysis showing the distance of the α-carbon atom of MET66 from the initial position as a function of time. (Right)
Superimposed snapshots illustrating the pulling pathway of the lid loop. The light red and blue cartoon or van der Waals renderings mark the lid loop’s open and
closed states, respectively. The rest of the LCAT enzyme is rendered as a grey cartoon representation. The black arrow indicates the movement of the lid loop during
the pulling simulations. The active site tunnel opening is marked with a yellow sphere.
https://doi.org/10.1371/journal.pcbi.1008426.g006
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compound 6’s interaction with the allosteric site of LCAT even if its entry is thermodynami-
cally favorable.
Nevertheless, our results suggest that the introduction of a pyrazine ring along with a charge
neutralization, is required for the entry into the allosteric site of LCAT, but it is not maybe crit-
ical when the activation of LCAT is mechanistically considered as indicated by compound 6’s
ability (in the neutral form) to induce an orientational change in the MBD. Therefore, the vari-
ation of chemical groups of the pyrazine ring or testing charge neutralizing modifications to
compound 6 might be the most effective avenues to improve the potencies of the current set of
positive allosteric modulators.
In addition to the existence of a higher free energy barrier, another speculative cause for
compound 6’s lack of binding could be its inability to participate in a favorable inter-protein
interaction. A pseudo-2-fold interface was detected in the crystal structure, where the tail
rings of compound 1b formed a bridge to the opposing LCAT [18]. Therefore, the forma-
tion of a homodimer could promote the binding of compounds with pyrazine rings by help-
ing them overcome a free energy barrier in the vicinity of the allosteric site. In addition, the
pyrazine ring may play a role in the binding of LCAT to the surface of HDL particles, as
recent structural evidence regarding the LCAT-HDL complex suggests that when bound to
the MBD the tail of compound 1b can interact with lipids or apoA-I at the surface of HDL
[42]. This in turn may affect the orientation and activity of LCAT at the lipid-water
interface.
More research needs to be done to elucidate the positive effect of the pyrazine ring on the
entry into LCAT, which would further characterize an optimal allosteric modulator. Regard-
less, although we could not establish a clear connection between the compounds’ binding ener-
gies or induced effects and their experimental potencies, the conformational change
discovered here provides a plausible explanation of the mechanism of the effect the com-
pounds elicit in LCAT. This is significant as the observed conformational change can be used
as a computational screening tool to discover and develop new positive allosteric modulators
for LCAT, benefiting the pharmaceutical research on LCAT related diseases.
Conclusions
In this research study, we aimed to characterize how a set of positive allosteric modulators
interact with LCAT, firstly, to produce new insights on how these modulators mechanistically
promote the activity and, secondly, shed light on the general activation mechanism of LCAT
mediated by different apolipoproteins, chiefly apoA-I. While no apparent differences in bind-
ing or mode of interaction were registered between the allosteric modulators that could
explain their different fold activities, we found out that all molecules, expect the charged form
of compound 6, can realign the MBD of LCAT. Further, our steered molecular dynamics sim-
ulations suggest that the MBD needs to retract away from the lid binding cavity during the
lid’s conformational shift from the closed to the open state and vice versa. Thus, we hypothe-
size that the realignment and the altered free energy landscape of the MBD induced by the pos-
itive allosteric modulators facilitate the activation of LCAT by making it easier for the lid loop
to alternate between open and closed conformations. This is because the MBD’s realignment
may either simply lessen the steric hindrances associated with the change or modulate the
transitional folding pathway’s energetics. The findings presented in this study can be possibly
validated by nuclear magnetic resonance studies or by producing crystal structures for LCAT
with solely an allosteric compound bound to LCAT without IDFP. To sum up, our findings
provide a plausible explanation of why the set of positive allosteric modulators studied here
increases the fold rate of LCAT. This information can be exploited to design new LCAT
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activating drug molecules to treat LCAT deficiencies and CVDs or further understand the acti-
vation mechanism of LCAT mediated by apoA-I.
Supporting information
S1 Text. Supporting Tables and Figures Table A The average number of hydrophobic inter-
actions between drugs and nearby amino acids as mean (SD). Table B Accessible surface areas
(ASA) of drugs in relevant contexts as mean (SD). Fig A The free-energy profiles (top) and
umbrella sampling converge (bottom) for compounds 6 and 8 calculated by utilizing the
umbrella sampling technique. Fig B The umbrella sampling histogram overlaps for compound
6 (10–50 ns) and 8 (50–90 ns). Fig C Steered molecular dynamics analysis with the force con-
stant of 500 kJ/mol�nm showing the distance of the α-carbon atom of MET66 from the initial
position as a function of time Fig D The converge of AWH simulations analyzed using simula-
tion intervals of 100 ns.
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Project administration: Artturi Koivuniemi.
Resources: Artturi Koivuniemi.
Supervision: Artturi Koivuniemi.
Visualization: Akseli Niemelä, Artturi Koivuniemi.
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